Under terms of the agreement, the companies will work together to upscale the established Xcimzane™ manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical trials as well as the Comparability Analytical Assessment required for regulatory filing.
“AGC is a high-quality partner with global manufacturing expertise, and we are pleased to enter into this agreement as the next step in the development of Xcimzane™ towards clinical trials” said Martin Åmark, CEO
“We are proud to be the partner of choice for this technically demanding biosimilar throughout the whole clinical phase” said
© Modular Finance, source